TY - JOUR T1 - Lessons from ECLIPSE: a review of COPD biomarkers JF - Thorax JO - Thorax SP - 666 LP - 672 DO - 10.1136/thoraxjnl-2013-204778 VL - 69 IS - 7 AU - Rosa Faner AU - Ruth Tal-Singer AU - John H Riley AU - Bartolomé Celli AU - Jørgen Vestbo AU - William MacNee AU - Per Bakke AU - Peter M A Calverley AU - Harvey Coxson AU - Courtney Crim AU - Lisa D Edwards AU - Nick Locantore AU - David A Lomas AU - Bruce E Miller AU - Stephen I Rennard AU - Emiel F M Wouters AU - Julie C Yates AU - Edwin K Silverman AU - Alvar Agusti Y1 - 2014/07/01 UR - http://thorax.bmj.com/content/69/7/666.abstract N2 - The Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study was a large 3-year observational controlled multicentre international study aimed at defining clinically relevant subtypes of chronic obstructive pulmonary disease (COPD) and identifying novel biomarkers and genetic factors. So far, the ECLIPSE study has produced more than 50 original publications and 75 communications to international meetings, many of which have significantly influenced our understanding of COPD. However, because there is not one paper reporting the biomarker results of the ECLIPSE study that may serve as a reference for practising clinicians, researchers and healthcare providers from academia, industry and government agencies interested in COPD, we decided to write a review summarising the main biomarker findings in ECLIPSE. ER -